Do you want to read an article? Please log in or register.
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis
Multiple Sclerosis
Related content
Multiple Sclerosis
Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis
JAMA Neurol.
Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C, Gobbi C, Kappos L, Derfuss T
doi: 10.1001/jamaneurol.
Multiple Sclerosis
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
Lancet Neurol.
Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I
doi: 10.1016/
Multiple Sclerosis
Long-term disability progression in primary progressive multiple sclerosis: a 15-year study
Brain.
Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M
doi: 10.1093/brain/awx250.
RECOMMENDED
Multiple Sclerosis
Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Mult Scler.
von Wyl V, Benkert P, Moser A, Lorscheider J, Décard B, Hänni P, Lienert C, Kuhle J, Derfuss T, Kappos L, Yaldizli Ö
doi: 10.1177/1352458520918489.
Multiple Sclerosis
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, MSBase Study Group
doi: 10.1001/jama.
Multiple Sclerosis
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
Ann Neurol.
Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L
doi: 10.1002/ana.25313.
Multiple Sclerosis
Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients
Ann Neurol.
Dalla Costa G, Martinelli V, Moiola L, Sangalli F, Colombo B, Finardi A,
Cinque P, Kolb EM, Haghikia A, Gold R, Furlan R, Comi G
doi: 10.1002/ana.25437.
RECOMMENDED
Multiple Sclerosis
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
Mult Scler.
Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J, Musch B, Giovannoni G
doi: 10.1177/1352458518808189.
Multiple Sclerosis
Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine
AJNR Am J Neuroradiol.
Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Silva D, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R
doi: 10.3174/ajnr.A5876.